免疫检查点抑制剂相关的1型糖尿病发病率,风险和存活率相关联
Fumika Kamitani1, Yuichi Nishioka2, Miyuki Koizumi1
1Department of Diabetes and Endocrinology, Nara Medical University, Kashihara, Nara, Japan.
Journal of diabetes investigation
|November 21, 2024
概括
免疫检查点抑制剂相关的1型糖尿病 (ICI-T1DM) 影响0.48%的患者. 发展ICI-T1DM与更高的存活率有关,尽管存在诸如组合疗法和先前自身免疫性疾病等危险因素.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
背景情况:
- 免疫检查点抑制剂 (ICI) 是关键的癌症疗法.
- 免疫检查点抑制剂相关的1型糖尿病 (ICI-T1DM) 是一种罕见但显著的不良事件.
- 了解ICI-T1DM发病率,风险因素和生存影响至关重要.
研究的目的:
- 为了确定ICI-T1DM的确切发病率.
- 确定与ICI-T1DM发展相关的风险因素.
- 评估ICI-T1DM对患者生存结果的影响.
主要方法:
- 使用日本行政索赔数据库 (1100万患者) 的回顾性队列研究.
- 包括21,121名在2014年至2022年期间接受ICI治疗的患者.
- 使用后勤回归和多变量考克斯回归分析来评估风险因素和生存率.
主要成果:
- ICI-T1DM发生在0.48%的患者中.
- 结合ICI治疗 (PD-(L) 1和CTLA-4) 和以前的糖尿病或甲状腺功能低下症增加了ICI-T1DM风险.
- 患有ICI-T1DM的患者表现出显著更高的生存率 (HR 0.60).
结论:
- 这项研究为ICI-T1DM提供了精确的发病率和风险因素数据.
- 类似于其他免疫相关的不良事件,ICI-T1DM与改善的生存结果有关.
- 调查结果强调了ICI-T1DM监测的重要性及其潜在的预后影响.
相关概念视频
Psychoneuroimmunology: Diabetes and Cancer
24
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
24
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Insulin: Dosing Regimen and Adverse Effects
145
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
145
Diabetes: Symptoms, Diagnosis, and Complications
506
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
506
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171


